Weekly Recap | AKESO -11.54%, most brokers rate it buyWeekly Review·Nov 21, 2026 at 05:59 AM09926-7.05%
Akeso falls 6% as FDA declines ivonescimab U.S. applicationMarket Movers·Nov 20, 2026 at 01:51 AM09926-7.05%
CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key CatalystAASTOCKS News·Nov 18, 2026 at 05:48 AM09926-7.05%
Daiwa Cuts AKESO TP to HKD120, Reiterates Buy; Decline Exceeds FundamentalsAASTOCKS News·Nov 17, 2026 at 07:58 AM09926-7.05%
CMB International Securities Keeps Their Buy Rating on Akeso, Inc. (9926)Tip Ranks·Nov 17, 2026 at 05:15 AM09926-7.05%
China Accepts Akeso’s Ivonescimab Application for Biliary Tract CancerPUBT·Nov 17, 2026 at 03:31 AM09926-7.05%
HSI Gains 116 Pts for Day; NEW WORLD DEV Plunges 40%, MINIMAX-W Hits New Low with 18% Drop, AKESO Slumps 22%AASTOCKS News·Nov 16, 2026 at 08:47 AM00100-10.80%00017+2.22%
HSI Closes at 23,753, Up 116 pts; HSTI Closes at 3,801, Down 11 pts; AKESO Down over 22%; MENGNIU DAIRY, CKI HOLDINGS, BANK OF CHINA, MIDEA GROUP, COSCO SHIP PORT Hit New Highs; Market Turnover RisesAASTOCKS News·Nov 16, 2026 at 08:13 AM01038+0.97%01199-1.91%
China’s Akeso Sinks After US FDA Rejects License Application for Its Cancer DrugYicai·Nov 16, 2026 at 07:53 AM09926-7.05%
Citi Cuts AKESO TP to HKD163 as US FDA Rejects New Lung Cancer DrugAASTOCKS News·Nov 16, 2026 at 07:32 AM09926-7.05%